Lyell Immunopharma, Inc. Marketable Securities (Current)
Lyell Immunopharma, Inc. (LYEL) had Marketable Securities (Current) of $131.12 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $131.12M.
- 2026-03-31: Marketable Securities, Current $163.25M.
- 2025-12-31: Marketable Securities, Current $187.04M.
- 2025-09-30: Marketable Securities, Current $196.05M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $131.12M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $163.25M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $187.04M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $196.05M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $177.99M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $180.85M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $264.93M 10-K · filed 2026-03-12 |
| 2024-09-30 | $340.25M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $357.69M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $400.65M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $400.58M 10-K · filed 2025-03-11 |
| 2023-09-30 | $289.22M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $371.38M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $503.34M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $516.60M 10-K · filed 2024-02-28 |
| 2022-09-30 | $531.82M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $449.82M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $391.32M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $320.97M 10-K · filed 2023-02-28 |
| 2021-09-30 | $225.42M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $260.08M 10-Q · filed 2021-08-12 |
| 2020-12-31 | $472.21M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |